Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma
Kaseb, Ahmed O., Shindoh, Junichi, Patt, Yehuda Z., Roses, Robert E., Zimmitti, Giuseppe, Lozano, Richard D., Hassan, Manal M., Hassabo, Hesham M., Curley, Steven A., Aloia, Thomas A., Abbruzzese, JamVolume:
119
Language:
english
Journal:
Cancer
DOI:
10.1002/cncr.28209
Date:
September, 2013
File:
PDF, 328 KB
english, 2013